TB-500, also known as Thymosin Beta-4 fragment, is a synthetic peptide version of a naturally occurring protein found in nearly all human and animal cells. Thymosin beta-4 plays a fundamental role in tissue repair and regeneration by promoting cell migration, blood vessel formation, and reducing inflammation.
As one of the most abundant intracellular peptides, thymosin beta-4 is a key regulator of actin — the protein responsible for forming the structural framework of cells. By sequestering G-actin monomers, it influences cell motility, which is essential for wound healing and tissue repair processes.
Research Applications
Published research has examined TB-500/Thymosin Beta-4 across multiple therapeutic areas:
- Wound healing: Dermal wound closure, corneal epithelial repair, surgical wound recovery
- Cardiac repair: Post-myocardial infarction tissue remodeling, cardiomyocyte survival
- Musculoskeletal: Muscle fiber repair, tendon and ligament healing, joint inflammation
- Neurological: Central and peripheral nervous system repair models, oligodendrocyte differentiation
- Anti-inflammatory: Cytokine modulation, fibrosis reduction in multiple organ models
Dosage Information (Research Use)
Research protocols documented in published literature:
- Loading phase: Higher initial doses for 4-6 weeks documented in some protocols
- Standard research range: 2-5 mg administered 1-2 times per week (scaled from animal models)
- Maintenance protocols: Reduced frequency after initial loading period
- Common administration: Subcutaneous injection
These reflect published research protocols. This compound is sold for research purposes only.
Reconstitution & Handling
Reconstitute TB-500 with bacteriostatic water:
- Add 1-2 mL BAC water per 5mg vial
- Direct water stream down the vial wall, not onto the powder
- Swirl gently until clear — do not shake or vortex
- Refrigerate at 2-8°C after reconstitution
Example: 5mg vial + 1mL BAC water = 5,000 mcg/mL. For a 2.5mg (2,500 mcg) dose, draw 50 units on a standard insulin syringe.
Half-Life & Pharmacokinetics
Thymosin beta-4 has a relatively short plasma half-life but demonstrates prolonged tissue-level activity due to intracellular accumulation and slow release from actin-binding complexes. Functional duration supports twice-weekly administration in most research protocols.
Reported Observations in Literature
Published research reports:
- Generally well-tolerated across animal and limited human data (Phase I/II dermal wound trials)
- Injection site reactions (temporary redness, mild discomfort) noted in some protocols
- Theoretical concern regarding proliferative effects in existing pathology — not confirmed in published data
- No systemic toxicity reported at research doses
Key Research References
- Goldstein AL, et al. “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med. 2005
- Bock-Marquette I, et al. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature. 2004
- Sosne G, et al. “Thymosin beta 4 promotes corneal wound healing.” Exp Eye Res. 2002